Recently, according to the official website of Beckman Coulter Life Sciences, Danaher subsidiary Beckman Coulter Life Sciences (hereinafter referred to as Beckman) announced the appointment of Joe Fox as president, effective immediately.

It is understood that Joe Fox is a veteran of Danaher. He served as president of Danaher subsidiary Sciex, and before becoming president, he held several leadership positions in the company, including senior vice president of global sales and services. In 13 years, Joe Fox has held positions with increasing responsibilities until he became president recently.

Before joining Sciex, Joe Fox held technical and commercial positions at Bruker and Shimadzu, and Joe Fox also holds a degree in biochemistry from the University of Delaware and a doctorate in chemistry from Johns Hopkins University. After taking office, Joe Fox will lead a global team of more than 3,300 employees to promote product and service innovation to provide solutions in areas such as workflow centrifugation, flow cytometry, genomics, particle analysis and liquid handling. In addition, Joe Fox will support Beckman's commitment to sustainability, including further integration of sustainability into operations, products and packaging. Beckman was founded in 1935 with the invention of a pH meter by Dr. Beckman that could be used to accurately measure the pH of lemon juice. From a small business in an auto repair shop in Pasadena, California, to a world giant in clinical diagnostics and life sciences today, Beckman's success is mainly attributed to three visionary scientists: Dr. Beckman and the Coulter brothers, who brought important changes to technology and medicine. In 1997, Beckman and Coulter merged to become today's Beckman Coulter Co., Ltd. In 2011, Danaher acquired Beckman for a high price of $6.8 billion.

Regarding Joe Fox's appointment, Greg Milosevich, Vice President of the Inclusion and Engagement Team for Life Sciences and Clinical Industries and Group Executive of Danaher Life Sciences Innovation Group, said: Joe is a recognized leader with a proven track record of successfully growing businesses and building diversification, and Joe has a unique understanding of Danaher's strategy, the culture of the Danaher Business System (DBS), and a firm commitment to customer excellence. Joe will help Beckman continue to provide meaningful innovative talent while cultivating and attracting top customers.

Beckman has developed rapidly since its establishment. Over the past 100 years, various instruments under the "Beckman" and "Kurt" brands have been widely recognized and accepted by medical personnel and scientific researchers around the world. Beckman's main products include flow cytometry research flow cytometry, clinical flow cytometry, centrifuges, automated liquid workstations, genomics, synthetic biology, cell health analysis, particle quality control tools, after-sales services, etc. Its products are mainly used in important cutting-edge research fields, including genomics, proteomics, cytomics, and biopharmaceuticals.

In recent years, Beckman's development momentum has continued to grow, and this growth momentum is also reflected in Danaher's financial report. On March 29, 2024, Danaher Group announced quarterly results. In the first quarter, Danaher's total revenue was US$5.8 billion, and diagnostic revenue was US$2.527 billion, accounting for 43.5%. Among them, the core sales of the diagnostic business increased by 7.5%, and it has achieved growth for five consecutive quarters. Beckman achieved single-digit growth, mainly due to the DxI900, DxC500 and DxA5000 products launched in recent years. It is reported that Beckman launched several new solutions in 2024 to improve laboratory workflows, including the CytoFLEX nano-flow cytometer, which completely changed the analysis of nanoparticles, the QbD1200+ total organic carbon analyzer, which can accelerate pharmaceutical and biopharmaceutical analysis, and the Biomek Echo One system for high-throughput genomic sample preparation. The company has also recently partnered with DLL Financial Solutions, a wholly-owned subsidiary of Rabobank, to make financing options more accessible. As an international leading IVD company, Beckman is also the earliest IVD company to be deployed in the Chinese market. Now that Beckman’s new president has taken office, a new atmosphere will be ushered in. We look forward to Beckman’s subsequent development.

https://mp.weixin.qq.com/